Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 438

1.

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.

Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity.

J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.

2.

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.

Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G.

JACC Cardiovasc Interv. 2012 Mar;5(3):281-9. doi: 10.1016/j.jcin.2012.01.009.

3.

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.

Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, Bessereau J, Lemesle G, Dignat-George F, Paganelli F, Camoin-Jau L.

J Thromb Haemost. 2012 Oct;10(10):1999-2005. doi: 10.1111/j.1538-7836.2012.04875.x.

4.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

5.

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Uhry S, Bessereau J, Camoin-Jau L, Paganelli F, Bonello L.

Hosp Pract (1995). 2012 Apr;40(2):104-17. doi: 10.3810/hp.2012.04.976. Review.

PMID:
22615085
6.

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC.

JACC Cardiovasc Interv. 2013 Aug;6(8):854-63. doi: 10.1016/j.jcin.2013.04.009.

7.

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.

Am J Cardiol. 2009 Oct 15;104(8):1078-82. doi: 10.1016/j.amjcard.2009.06.007.

PMID:
19801028
8.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity.

J Am Coll Cardiol. 2010 Sep 14;56(12):919-33. doi: 10.1016/j.jacc.2010.04.047.

9.

Impact of initial clinical presentation on clopidogrel low response.

Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.

Arch Cardiovasc Dis. 2013 Nov;106(11):593-600. doi: 10.1016/j.acvd.2013.06.050. Epub 2013 Sep 23.

10.

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.

Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D.

Thromb Haemost. 2014 Aug;112(2):342-51. doi: 10.1160/TH13-10-0874. Epub 2014 Apr 10.

PMID:
24718389
11.

Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.

Varenhorst C, Koul S, Erlinge D, Lagerqvist B, Siegbahn A, Wallentin L, James S.

Am Heart J. 2011 Aug;162(2):363-71. doi: 10.1016/j.ahj.2011.06.003. Epub 2011 Jul 20.

PMID:
21835299
12.

Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.

Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH.

JACC Cardiovasc Interv. 2012 Mar;5(3):259-67. doi: 10.1016/j.jcin.2011.12.009.

13.
14.

High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.

Leé S, Vargová K, Hizoh I, Horváth Z, Gulácsi-Bárdos P, Sztupinszki Z, Apró A, Kovács A, Préda I, Tóth-Zsámboki E, Kiss RG.

Thromb Res. 2014 Feb;133(2):257-64. doi: 10.1016/j.thromres.2013.11.029. Epub 2013 Dec 6.

PMID:
24359966
15.

Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.

JACC Cardiovasc Interv. 2010 Jun;3(6):648-56. doi: 10.1016/j.jcin.2010.03.003.

16.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
17.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

18.

A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.

Straub N, Beivers A, Lenk E, Aradi D, Sibbing D.

Thromb Haemost. 2014 Feb;111(2):290-9. doi: 10.1160/TH13-08-0679. Epub 2013 Oct 24.

PMID:
24154566
19.

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

Laine M, Camoin-Jau L, Bessereau J, Sébastien A, Paganelli F, Bonello L.

Curr Pharm Des. 2012;18(33):5392-401. Review.

PMID:
22724420
20.

Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.

Rosengart TK, Romeiser JL, White LJ, Fratello A, Fallon E, Senzel L, Shroyer AL.

J Thorac Cardiovasc Surg. 2013 Nov;146(5):1259-1266, 1266.e1; discussion 1266. doi: 10.1016/j.jtcvs.2013.06.029. Epub 2013 Aug 13.

Items per page

Supplemental Content

Write to the Help Desk